page header

Contents  ·  Introduction  ·  Learning  Objectives  ·  Textbook  ·  Lectures  ·  Procedures  ·  Final Exam  ·  Library  ·  Laboratory  ·  Pharmacy  ·  Imaging  ·  Forms  ·  Videos  ·  About  ·  Contact Us>

Polymyxin B Sulfate Injection

Category:

  • Antibiotic

Description:

  • Topical anti-infective

Indications:

  • Acute infections due to P. aeruginosa

  • Serious infections from  H. influenzae, E. coli, Enterobacter aerogenes, Klebsiella pneumoniae)

  • NOTE: for meningeal infections, administer  intrathecally

Contraindications:

  • None

Precautions:

  • Pregnancy category B

  • Monitor patient’s renal function with baseline levels and throughout therapy

  • May cause neurotoxic reactions such as:

    • irritability

    • weakness

    • drowsiness

    • ataxia

    • peripheral numbness

    • blurred vision

    • Severe neurotoxicity may lead to respiratory paralysis if given shortly after anesthesia or muscle relaxants.

Adverse Reactions (Side Effects):

  • Nephrotoxic: 

    • albuminuria

    • cylindruria

    • azotemia

  • Neurotoxic: 

    • facial flushing

    • dizziness

    • drowsiness

    • apnea

    • peripheral paresthesia

  • Meningeal irritation in intrathecal administration

  • Drug fever

  • Urticarial rash

  • Severe pain or thrombophlebitis at injection site  

Dosage:

  • Administered by IV or IM injection

  • IV administration:

    • Adults and Children (normal renal function): 15,000-25,000 units/kg/day in divided doses q12h

    • Infants: 40,000 units/kg/day

  • IM administration:

    • Adults and Children (normal renal function): 25,000-30,000 units/kg/day in divided doses at 4-6 hour intervals

    • Infants: 40,000 units/kg/day

  • Intrathecal administration:

    • Adults and Children (>2 years old) (normal renal function): 50,000 units once daily for 3-4 days, then 50,000 units once every other day for at least two weeks once CSF culture is negative

    • Children (<2 years old): 20,000 units once daily, then 25,000 units once every other day for at least two weeks once CSF culture is negative

 

 

 


The information contained here is an abbreviated summary. For more detailed and complete information, consult the manufacturer's product information sheets or standard textbooks

Source: Operational Medicine 2001,  Health Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington, D.C., 20372-5300

This information is provided by The Brookside Associates.  The Brookside Associates, LLC. is a private organization, not affiliated with any governmental agency. The opinions presented here are those of the author and do not necessarily represent the opinions of the Brookside Associates or the Department of Defense. The presence of any advertising on these pages does not constitute an endorsement of that product or service by either the US Department of Defense or the Brookside Associates. All material presented here is unclassified.

C. 2009, 2014, All Rights Reserved

brookside associates logo

 

 

 

 

 

Advertise on this site